These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 22030942)

  • 21. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention.
    Scarpignato C; Hunt RH
    Gastroenterol Clin North Am; 2010 Sep; 39(3):433-64. PubMed ID: 20951911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA; Dobesh PP; Trujillo TC
    Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Chan FK; Abraham NS; Scheiman JM; Laine L;
    Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
    Lanas A; Ferrandez A
    Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topical nonsteroidal anti-inflammatory drugs for osteoarthritis.
    Barthel HR; Axford-Gatley RA
    Postgrad Med; 2010 Nov; 122(6):98-106. PubMed ID: 21084786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events.
    Chan AT; Manson JE; Albert CM; Chae CU; Rexrode KM; Curhan GC; Rimm EB; Willett WC; Fuchs CS
    Circulation; 2006 Mar; 113(12):1578-87. PubMed ID: 16534006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Appropriate use of NSAIDs: considering cardiovascular risk in the elderly.
    Stillman MJ; Stillman MT
    Geriatrics; 2007 Mar; 62(3):16-21. PubMed ID: 17346094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practical considerations for the pharmacologic management of osteoarthritis.
    Altman RD
    Am J Manag Care; 2009 Sep; 15(8 Suppl):S236-43. PubMed ID: 19817510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COX-2 selective inhibitors in the treatment of osteoarthritis.
    Laine L; White WB; Rostom A; Hochberg M
    Semin Arthritis Rheum; 2008 Dec; 38(3):165-87. PubMed ID: 18177922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NSAIDs-induced gastrointestinal damage. Review.
    Arroyo M; Lanas A
    Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs.
    Farkouh ME; Greenberg BP
    Am J Cardiol; 2009 May; 103(9):1227-37. PubMed ID: 19406264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O; Solomon SD
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan.
    Chang CH; Chen HC; Lin JW; Kuo CW; Shau WY; Lai MS
    Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):763-71. PubMed ID: 21618340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cardiovascular risk of non-steroidal anti-inflammatory drugs].
    Hermann M
    Praxis (Bern 1994); 2012 Oct; 101(20):1309-14. PubMed ID: 23032496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NSAID-induced gastrointestinal and cardiovascular injury.
    Ng SC; Chan FK
    Curr Opin Gastroenterol; 2010 Nov; 26(6):611-7. PubMed ID: 20948372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs.
    Jones R; Rubin G; Berenbaum F; Scheiman J
    Am J Med; 2008 Jun; 121(6):464-74. PubMed ID: 18501223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.